Potential liver toxicity in diabetics using Rezulin (troglitazone)

    There's a growing concern about potential liver toxicity in diabetics using Rezulin (troglitazone).

    Rezulin has been given to over half a million patients since it came out early last year.

    But now there are over 150 reports of possible liver dysfunction...resulting in one liver transplant and several deaths.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote